What is Invivoscribe?
Invivoscribe is a leader in the development of precision molecular diagnostic assays, reagents, software, and clinical laboratory services. The company's offerings are crucial for physicians in detecting and monitoring blood cancers, guiding treatment decisions, and supporting personalized oncology care via companion diagnostics and biomarker testing. This focus positions Invivoscribe at the forefront of the rapidly evolving field of targeted cancer therapies.
How much funding has Invivoscribe raised?
Invivoscribe has raised a total of $5M across 1 funding round:
Debt
$5M
Debt (2020): $5M with participation from PPP
Key Investors in Invivoscribe
PPP
Public-Private Partnership
What's next for Invivoscribe?
The recent major strategic investment signals a new phase of growth and development for Invivoscribe. This capital infusion is expected to accelerate the expansion of its diagnostic platforms, enhance its clinical laboratory services, and potentially broaden its market reach. The company is poised to further solidify its position in the precision medicine landscape, driving innovation in cancer diagnostics and patient care.
See full Invivoscribe company page
